Literature DB >> 10947302

Assessing health utilities in schizophrenia. A feasibility study.

L N Voruganti1, A G Awad, L K Oyewumi, L Cortese, S Zirul, R Dhawan.   

Abstract

BACKGROUND: Utility, a concept derived from economics, is the desirability or preference that individuals exhibit for a certain health state. Utility measurement could be viewed as an alternative means of appraising the quality of life of individuals affected by a chronic illness such as schizophrenia. Traditional techniques of utility measurement involve 2 steps: (i) identifying the different health states experienced by individuals during the course of an illness; and (ii) assigning them numerical values known as utilities. AIM: The study examined the feasibility issues and psychometric aspects of obtaining accurate health state descriptions and their utilities from symptomatically stable patients with schizophrenia.
METHODS: The study used a cross-sectional, case-controlled design, with a study group consisting of 120 clinically stabilised patients with schizophrenia and a control group of 32 treated and recovered patients with major depression. Patients were asked to provide detailed descriptions of 3 distinct health states associated with their illness: current state, worst state experienced since the onset of illness and a perfect state desired in the future. Further, patients were asked to assign utilities to these health states with the aid of a purpose-built evaluation protocol comprising Magnitude Estimation (ME), Rating Scale (RS), Standard Gamble (SG), Time Trade-Off (TTO) and Willingness-to-Pay (WTP) techniques. The battery was repeated after a 1-week interval. Independent raters assessed symptom severity, insight and quality of life, and nurse-clinicians involved in their care were asked to provide the utility ratings of their clients' mental health state. Patients' opinions about the acceptability of utility measurement techniques, and the respondent burden were also ascertained.
RESULTS: Compared with control patients with treated depression, patients with schizophrenia were able to distinguish and describe the specified health states with an equal degree of ease and accuracy. RS, TTO and WTP techniques emerged as the favoured methods of utility evaluation. The test-retest reliability of utility ratings (r = 0.87 to 0.97; p < 0.001) was high, and concurrent validity with the quality of life measures was acceptable. Reliability and validity of patients' appraisals were unaffected by symptoms severity and insight. The accuracy of nurse-clinicians' appraisals were dependent on their close familiarity with the patients and their illness.
CONCLUSION: Clinically stabilised patients with schizophrenia can provide accurate health state descriptions and assign them utilities with a fair degree of reliability and validity. Utility evaluations based on patients' self-appraisals can be seen as potential tools in outcome studies and clinical trials involving patients with schizophrenia, but the methodology requires further refinement to accommodate the limitations imposed by the patients' disturbed mental status.

Entities:  

Mesh:

Year:  2000        PMID: 10947302     DOI: 10.2165/00019053-200017030-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  22 in total

1.  Quality of life of seriously mentally ill persons in Mississippi.

Authors:  G Sullivan; K B Wells; B Leake
Journal:  Hosp Community Psychiatry       Date:  1991-07

Review 2.  Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry.

Authors:  D A Revicki; B R Luce
Journal:  Psychopharmacol Bull       Date:  1995

Review 3.  Pharmacoeconomics of antipsychotic drug therapy.

Authors:  W A Hargreaves; M Shumway
Journal:  J Clin Psychiatry       Date:  1996       Impact factor: 4.384

4.  The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance.

Authors:  J Endicott; R L Spitzer; J L Fleiss; J Cohen
Journal:  Arch Gen Psychiatry       Date:  1976-06

5.  Relationship between health utility and psychometric health status measures.

Authors:  D A Revicki
Journal:  Med Care       Date:  1992-05       Impact factor: 2.983

Review 6.  Utility approach to measuring health-related quality of life.

Authors:  G W Torrance
Journal:  J Chronic Dis       Date:  1987

7.  Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings.

Authors:  D A Revicki; R E Brown; M B Keller; J Gonzales; L Culpepper; R E Hales
Journal:  J Clin Psychiatry       Date:  1997-02       Impact factor: 4.384

8.  Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life.

Authors:  L Voruganti; L Cortese; L Oyewumi; Z Cernovsky; S Zirul; A Awad
Journal:  Schizophr Res       Date:  2000-06-16       Impact factor: 4.939

9.  Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol.

Authors:  G Chouinard; P S Albright
Journal:  J Clin Psychopharmacol       Date:  1997-08       Impact factor: 3.153

10.  Cost-utility analysis in schizophrenia.

Authors:  A G Awad; L P Voruganti
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

View more
  15 in total

1.  Valuation of depression co-occurring with a somatic condition: feasibility of the time trade-off task.

Authors:  Katerina Papageorgiou; Karin M Vermeulen; Fenna R M Leijten; Erik Buskens; Adelita V Ranchor; Maya J Schroevers
Journal:  Health Expect       Date:  2014-11-13       Impact factor: 3.377

2.  Estimation and comparison of derived preference scores from the SF-36 in lung transplant patients.

Authors:  Francis S Lobo; Cynthia R Gross; Barbara J Matthees
Journal:  Qual Life Res       Date:  2004-03       Impact factor: 4.147

Review 3.  A review and critique of studies reporting utility values for schizophrenia-related health states.

Authors:  Ifigeneia Mavranezouli
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 4.  Measuring quality of life in patients with schizophrenia: an update.

Authors:  A George Awad; Lakshmi N P Voruganti
Journal:  Pharmacoeconomics       Date:  2012-03       Impact factor: 4.981

5.  Outcome revealed by preference in schizophrenia (OPS): development of a new class of outcome measurements.

Authors:  Bruno Falissard; Nadine Bazin; Marie-Christine Hardy-Bayle
Journal:  Int J Methods Psychiatr Res       Date:  2006       Impact factor: 4.035

6.  Valuing health in a racially and ethnically diverse community sample: an analysis using the valuation metrics of money and time.

Authors:  Norah E Mulvaney-Day; Marcela Horvitz-Lennon; Chih-Nan Chen; Mara Laderman; Margarita Alegría
Journal:  Qual Life Res       Date:  2010-08-01       Impact factor: 4.147

7.  Ethnicity and diagnostic patterns in veterans with psychoses.

Authors:  Frederic C Blow; John E Zeber; John F McCarthy; Marcia Valenstein; Leah Gillon; C Raymond Bingham
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2004-10       Impact factor: 4.328

Review 8.  Impact of atypical antipsychotics on quality of life in patients with schizophrenia.

Authors:  A George Awad; Lakshmi N P Voruganti
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

9.  Cost-benefit analysis of first-generation antihistamines in the treatment of allergic rhinitis.

Authors:  Patrick W Sullivan; Sheryl L Follin; Michael B Nichol
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

10.  Utility assessment in patients with mental disorders: validity and discriminative ability of the time trade-off method.

Authors:  Hans-Helmut König; Oliver H Günther; Matthias C Angermeyer; Christiane Roick
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.